ES2632443T3 - Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH - Google Patents
Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH Download PDFInfo
- Publication number
- ES2632443T3 ES2632443T3 ES12833476.0T ES12833476T ES2632443T3 ES 2632443 T3 ES2632443 T3 ES 2632443T3 ES 12833476 T ES12833476 T ES 12833476T ES 2632443 T3 ES2632443 T3 ES 2632443T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- dihydro
- butoxy
- oxo
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title 1
- ORKUYZDMEWAUEZ-UHFFFAOYSA-N pyrrolo[3,2-b]pyridin-2-one Chemical class N1=CC=CC2=NC(=O)C=C21 ORKUYZDMEWAUEZ-UHFFFAOYSA-N 0.000 title 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract description 41
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 38
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract description 24
- -1 2 - (piperidin-1-yl) ethyl Chemical group 0.000 abstract description 23
- 150000001875 compounds Chemical class 0.000 abstract description 23
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 6
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 96
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 abstract 17
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 abstract 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- TVSLNRQODQRVJZ-UHFFFAOYSA-N 2-(3,4,5-trifluorophenyl)acetonitrile Chemical group FC1=CC(CC#N)=CC(F)=C1F TVSLNRQODQRVJZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 17
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 11
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 10
- 229960000311 ritonavir Drugs 0.000 description 10
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- 229960002049 etravirine Drugs 0.000 description 2
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 2
- 229950008687 oltipraz Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- CNPVJJQCETWNEU-CYFREDJKSA-N (4,6-dimethyl-5-pyrimidinyl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone Chemical compound N([C@@H](COC)C=1C=CC(=CC=1)C(F)(F)F)([C@H](C1)C)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)N=CN=C1C CNPVJJQCETWNEU-CYFREDJKSA-N 0.000 description 1
- QRPZBKAMSFHVRW-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione Chemical compound C1=2NC=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 QRPZBKAMSFHVRW-UHFFFAOYSA-N 0.000 description 1
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- OKGPFTLYBPQBIX-CQSZACIVSA-N 1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CC=NC=2NC=C1C(=O)C(=O)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 OKGPFTLYBPQBIX-CQSZACIVSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- HSBKFSPNDWWPSL-VDTYLAMSSA-N 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1C=C[C@H](CO)O1 HSBKFSPNDWWPSL-VDTYLAMSSA-N 0.000 description 1
- CGBYTKOSZYQOPV-ASSBYYIWSA-N 5-chloro-3-[[3-[(e)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1h-indole-2-carboxamide Chemical compound C1([P@](=O)(C=2C3=CC(Cl)=CC=C3NC=2C(N)=O)OC)=CC(C)=CC(\C=C\C#N)=C1 CGBYTKOSZYQOPV-ASSBYYIWSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108010036239 CD4-IgG(2) Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- MCPUZZJBAHRIPO-UHFFFAOYSA-N Lersivirine Chemical compound CCC1=NN(CCO)C(CC)=C1OC1=CC(C#N)=CC(C#N)=C1 MCPUZZJBAHRIPO-UHFFFAOYSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 241001116459 Sequoia Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
- IBHARWXWOCPXCR-WELGVCPWSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](COP(O)(=O)OCC(CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 IBHARWXWOCPXCR-WELGVCPWSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 229950004424 alovudine Drugs 0.000 description 1
- 229950005846 amdoxovir Drugs 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229950009079 brecanavir Drugs 0.000 description 1
- JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- XNHZXMPLVSJQFK-UHFFFAOYSA-O dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium Chemical compound C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 XNHZXMPLVSJQFK-UHFFFAOYSA-O 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229960002542 dolutegravir Drugs 0.000 description 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003586 elvitegravir Drugs 0.000 description 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
- 229950006528 elvucitabine Drugs 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- SWMDAPWAQQTBOG-UHFFFAOYSA-N fostemsavir Chemical compound C1=2N(COP(O)(O)=O)C=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 SWMDAPWAQQTBOG-UHFFFAOYSA-N 0.000 description 1
- 229950010812 fostemsavir Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229950004697 lasinavir Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 229950004188 lersivirine Drugs 0.000 description 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
- 229950006243 loviride Drugs 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229940072250 norvir Drugs 0.000 description 1
- 229950006460 palinavir Drugs 0.000 description 1
- RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- 229950009860 vicriviroc Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto seleccionado entre el grupo que consiste en: ácido 2-(1-bencil-4-(4-clorofenil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(terc-butoxi)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(4-fluorobencil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(4-metoxibencil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(2-metoxietil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-isobutil-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido (S)-2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(3,4-difluorobencil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-6-metil-7-oxo-1-(2-(piperidin-1-il)etil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-6-metil-7-oxo-1-(2-(piperidin-1-il)etil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-6-metil-7-oxo-1-((5-(trifluorometil)furan-2-il)metil)-6,7-dihidro-1H-pirrol[2,3- c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(imidazo[1,2-a]piridin-2-ilmetil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3- c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-6-metil-1-((2-metiltiazol-4-il)metil)-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin- 5-il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(2-((2-hidroxi-4-metilfenil)amino)-2-oxoetil)-6-metil-7-oxo-6,7-dihidro-1Hpirrol[ 2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-6-metil-7-oxo-1-(1-feniletil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(1-bencil-3-bromo-4-(4-clorofenil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(tercbutoxi) acético, ácido 2-(1-bencil-4-(4-clorofenil)-3,6-dimetil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(terc-butoxi)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-((4-fluorofenil)sulfonil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, 30 ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-6-metil-7-oxo-1-tosil-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-((1-(2-hidroxietil)-1H-1,2,3-triazol-4-il)metil)-6-metil-7-oxo-6,7-dihidro-1Hpirrol[ 2,3-c]piridin-5-il)acético, ácido 2-(1-bencil-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(terc-butoxi)acético, ácido 2-(1- (benzo[c][1,2,5]oxadiazol-5-ilmetil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(terc35 butoxi)acético, ácido 2-(1-(4-boronobencil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(terc-butoxi)acético, ácido 2-(terc-butoxi)-2-(1-(4-carbamoilbencil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(6-metil-7-oxo-4-(p-tolil)-1-(4-((trifluorometil)tio)bencil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido (S)-2-(terc-butoxi)-2-(1-(4-fluorobencil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(6-metil-7-oxo-1-(tiofen-2-ilmetil)-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(1-(4-fluorofenetil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(6-metil-1-(4-(metilsulfonil)bencil)-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(1-(3,4-difluorobencil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(1-(4-metoxibencil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(1,6-dimetil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(1-(4-cloro-3-fluorobencil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(6-metil-7-oxo-4-(p-tolil)-1-(3,4,5-trifluorobencil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(1-(benzo[d][1,3]dioxol-5-ilmetil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(tercbutoxi) acético, ácido 2-(terc-butoxi)-2-(1-(4-fluorofenil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(1-(2-((4-fluorofenil)amino)-2-oxoetil)-6-metil-7-oxo-4-(p-tolil)-6,7-dihidro-1H-pirrol[2,3- c]piridin-5-il)acético, ácido 2-(terc-butoxi)-2-(1-(4-fluorobencil)-4-(4-metoxifenil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(terc-butoxi)-2-(1-(4-fluorobencil)-4-(4-fluorofenil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5- il)acético, ácido 2-(1-bencil-6-metil-4-(5-metilcroman-6-il)-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(terc-butoxi)acético, ácido 2-(1-bencil-6-metil-4-(5-metilcroman-6-il)-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)-2-(terc-butoxi)acético, ácido 2-(terc-butoxi)-2-(1,6-dimetil-4-(5-metilcroman-6-il)-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético,
Description
que incluyen cada uno de los compuestos. Como alternativa, la combinación puede administrarse por separado de una manera secuencial en la que se administra primero un agente de tratamiento y el otro segundo o viceversa. Dicha administración secuencial puede ser próxima temporalmente o remota temporalmente. Las cantidades del compuesto o compuestos de la invención o sales de los mismos y el otro u otros agentes farmacéuticamente activos
5 y los tiempos relativos de administración se seleccionarán con el fin de conseguir el efecto terapéutico combinado deseado.
Como tal, los compuestos de la presente invención pueden usarse en combinación con uno o más agentes útiles en la prevención o tratamiento del VIH.
Ejemplos de tales agentes incluyen:
10 inhibidores nucleotídicos de la transcriptasa inversa tales como zidovudina, didanosina, lamivudina, zalcitabina, abacavir, estavudina, adefovir, adefovir dipivoxilo, fozivudina, todoxilo, emtricitabina, alovudina, amdoxovir, elvucitabina y agentes similares; inhibidores no nucleótidos de la transcriptasa inversa (que incluyen un agente que tiene actividad antioxidante, tal como immunocal, oltipraz, etc.) tal como nevirapina, delavirdina, efavirenz, lovirida, immunocal, oltipraz,
15 capravirina, lersivirina, GSK2248761, TMC-278, TMC-125, etravirina y agentes similares; inhibidores de la proteasa tales como saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir y agentes similares; Inhibidores de la entrada, unión y fusión, tales como enfuvirtide (T-20), T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 y BMS-626529, 5-Helix y agentes similares;
20 Inhibidores de la integrasa, tales como raltegravir, elvitegravir, GSK1349572, GSK1265744 y agentes similares; inhibidores de la maduración, tales como PA-344 y PA-457 y agentes similares; e inhibidores de CXCR4 y/o CCR5, tales como vicriviroc (Sch-C), Sch-D, TAK779, maraviroc (UK 427.857), TAK449, así como los divulgados en los documentos WO 02/74769, PCT/US03/39644, PCT/US03/39975, PCT/US03/39619, PCT/US03/39618, PCT/US03/39740 y PCT/US03/39732 y agentes similares.
25 El ámbito de las combinaciones de compuestos de esta invención con agentes VIH no se limita a los mencionados anteriormente, sino que incluye, en principio, cualquier combinación con cualquier composición farmacéutica útil para el tratamiento del VIH. Como se ha indicado, en tales combinaciones los compuestos de la presente invención y otros agentes del VIH pueden administrarse por separado o conjuntamente. Además, un agente puede ser anterior, concurrente o posterior a la administración de otro agente o agentes.
30 La presente invención puede usarse en combinación con uno o más agentes útiles como potenciadores farmacológicos así como con o sin compuestos adicionales para la prevención o tratamiento del VIH. Ejemplos de tales potenciadores farmacológicos (o refuerzos farmacocinéticos) incluyen, pero sin limitación, ritonavir, GS-9350 y SPI-452.
El ritonavir es ácido 10-hidroxi-2-metil-5-(1-metiletil)-1-1[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)
35 2,4,7,12-tetraazatridecan-13-óico, 5-tiazolilmetil éster, [5S-(5S*,8R*,10R*,11R*)] y está disponible de Abbott Laboratories (Abbott Park, Illinois) como Norvir. Ritonavir es un inhibidor de la proteasa del VIH indicado con otros agentes antirretrovirales para el tratamiento de la infección por VIH. El ritonavir también inhibe el metabolismo del fármaco mediado por P450, así como el sistema de transporte de células de la P-glicoproteína (Pgp), dando lugar de este modo a concentraciones aumentadas de compuesto activo dentro del organismo.
40 GS-9350 es un compuesto que está siendo desarrollado por Gilead Sciences de Foster City California como un potenciador farmacológico.
SPI-452 es un compuesto que está siendo desarrollado por Sequoia Pharmaceuticals de Gaithersburg, Maryland, como un potenciador farmacológico.
En una realización de la presente invención, se usa un compuesto de la invención en combinación con ritonavir. En
45 una realización, la combinación es una combinación oral de dosis fija. En otra realización, el compuesto de la invención se formula en forma de una inyección parenteral de acción prolongada y el ritonavir se formula en forma de una composición oral. En una realización, es un kit que contiene el compuesto de la invención formulado en forma de una inyección parenteral de acción prolongada y el ritonavir se formula en forma de una composición oral. En otra realización, el compuesto de la invención se formula en forma de una inyección parenteral de acción
50 prolongada y el ritonavir se formula en forma de una composición inyectable. En una realización, es un kit que contiene el compuesto de la invención formulado en forma de una inyección parenteral de acción prolongada y el ritonavir se formula en forma de una composición inyectable.
En otra realización de la presente invención, se usa un compuesto de la invención en combinación GS-9350. En una realización, la combinación es una combinación oral de dosis fija. En otra realización, el compuesto de la invención
55 se formula en forma de una inyección parenteral de acción prolongada y el GS-9350 se formula en forma de una composición oral. En una realización, es un kit que contiene el compuesto de la invención formulado en forma de una inyección parenteral de acción prolongada y el GS-9350 se formula en forma de una composición oral. En otra realización, el compuesto de la invención se formula en forma de una inyección parenteral de acción prolongada y el
8
Etapa B
2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(4-fluorobencil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acetato de metilo
5 Una solución de 2-(terc-butoxi)-2-(4-(4-clorofenil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acetato de metilo (20 mg, 0,043 mmol) en acetonitrilo (0,5 ml) se trató con cloruro 4-fluorobencilo (0,025 ml, 0,213 mmol) y Cs2CO3 (69 mg, 0,213mmol) y después se agitó a 70 °C durante 2 horas. La mezcla se diluyó con agua y después se extrajo con acetato de etilo. Los extractos combinados se lavaron con salmuera, se secaron sobre Na2SO4, se filtraron y se concentraron y se concentraron para proporcionar 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(4-fluorobencil)-6
10 metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acetato de metilo en forma de un sólido de color amarillo claro que se usó sin ninguna purificación adicional. CLEM (m/z) ES+ = 511 (M+1).
Etapa C
Ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(4-fluorobencil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5il)acético
El compuesto del título se preparó de una manera similar a la que se describe en el ejemplo 1 y se aisló en forma de
15 un sólido de color blanco (6,1 mg, 0,012 mmol, rendimiento del 29 %) después de purificación por cromatografía de fase inversa (MeCN al 10-90 %/H2O-TFA al 0,1 %, 12 min). RMN 1H (400 MHz, CLOROFORMO-d) ppm 7,58 -7,67 (m, 1 H) 7,43 -7,51 (m, 2 H) 7,37 -7,44 (m, 1 H) 7,24 -7,33 (m, 2 H) 6,97 -7,05 (m, 3 H) 5,96 -6,02 (m, 1 H) 5,75 -5,86 (m, 2 H) 5,30 -5,36 (m, 1 H) 3,67 (s, 3 H) 1,00 (s, 9 H); CLEM (m/z) ES+ = 497 (M+1).
Ejemplo 3
20 Ácido 2-(terc-butoxi)-2-(4-(4-clorofenil)-1-(4-metoxibencil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acético
El compuesto del título se preparó de una manera similar a la que se describe en el ejemplo 2 a partir de 2-(tercbutoxi)-2-(4-(4-clorofenil)-6-metil-7-oxo-6,7-dihidro-1H-pirrol[2,3-c]piridin-5-il)acetato de metilo y cloruro de 4metoxibencilo. RMN 1H (400 MHz, CLOROFORMO-d) ppm 7,57 -7,64 (m, 1 H) 7,43 -7,49 (m, 2 H) 7,37 -7,43 (m, 1
25 H) 7,24 -7,29 (m, 2 H) 6,99 -7,06 (m, 1 H) 6,83 -6,90 (m, 2 H) 5,93 -6,00 (m, 1 H) 5,70 -5,83 (m, 2 H) 5,30 -5,36 (m, 1 H) 3,79 (s, 3 H) 3,68 (s, 3 H) 1,01 (s, 9 H); CLEM (m/z) ES+ = 509 (M+1).
42
(continuación)
- Número de compuesto (de la tabla 1)
- Ensayo VIH de MT4 CI50 (µM)
- 15
- 1,62
- 16
- 1,80
- 17
- 1,20
- 18
- 50,00
- 19
- 0,08
- 20
- 0,16
- 21
- 2,70
- 22
- 8,70
- 23
- 1,50
- 24
- 0,04
- 25
- 0,22
- 26
- 2,25
- 27
- 3,85
- 28
- 0,08
- 29
- 0,17
- 30
- 1,10
- 31
- 0,11
- 32
- 0,08
- 33
- 0,21
- 34
- 0,77
- 35
- 1,00
- 36
- 0,06
- 37
- 0,67
- 38
- 0,07
- 39
- 1,36
- 40
- 0,50
- 41
- 0,01
- 42
- 0,54
- 43
- 1,10
- 44
- 0,05
- 45
- 0,08
- 46
- 0,09
- 47
- 0,04
- 48
- 0,03
- 49
- 0,04
- 50
- 0,23
110
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161537649P | 2011-09-22 | 2011-09-22 | |
| US201161537649P | 2011-09-22 | ||
| PCT/US2012/055838 WO2013043553A1 (en) | 2011-09-22 | 2012-09-18 | Pyrrolopyridinone compounds and methods for treating hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2632443T3 true ES2632443T3 (es) | 2017-09-13 |
Family
ID=47914784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12833476.0T Active ES2632443T3 (es) | 2011-09-22 | 2012-09-18 | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9012642B2 (es) |
| EP (1) | EP2757887B1 (es) |
| ES (1) | ES2632443T3 (es) |
| WO (1) | WO2013043553A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG186821A1 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
| SG194512A1 (en) | 2011-04-21 | 2013-12-30 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| CN105121418A (zh) | 2012-04-20 | 2015-12-02 | 吉利德科学公司 | 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途 |
| TW201441197A (zh) | 2013-01-31 | 2014-11-01 | Shionogi & Co | Ｈｉｖ複製抑制劑 |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9315501B2 (en) * | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| ES2654242T3 (es) | 2014-02-12 | 2018-02-12 | Viiv Healthcare (No.5) Limited | Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana |
| EP3152215A1 (en) | 2014-02-18 | 2017-04-12 | ViiV Healthcare UK (No.5) Limited | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| EP3116879A1 (en) | 2014-02-18 | 2017-01-18 | VIIV Healthcare UK (No.5) Limited | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
| WO2015174511A1 (ja) | 2014-05-16 | 2015-11-19 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する３環性複素環誘導体 |
| AU2015293578B2 (en) * | 2014-07-21 | 2017-10-05 | Viiv Healthcare Uk Limited | Phenyl and tertbutylacetic acid substituted pyridinones having anti-HIV effects |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| SG11201709634QA (en) | 2015-05-29 | 2017-12-28 | Shionogi & Co | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| AU2017281286B2 (en) | 2016-06-20 | 2021-05-20 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| WO2018020357A1 (en) | 2016-07-25 | 2018-02-01 | Viiv Healthcare Uk Limited | Indoline derivatives |
| WO2018047002A1 (en) * | 2016-09-12 | 2018-03-15 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| WO2018047013A1 (en) * | 2016-09-12 | 2018-03-15 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
| CN109996563A (zh) * | 2016-09-12 | 2019-07-09 | St知识产权控股公司 | 4-甲基-5-(吡嗪-2-基)-3h-1,2-二硫杂环戊烯-3-硫酮的制剂、味道改良的制剂及其制备和使用方法 |
| JP2019531344A (ja) | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
| EP3728256B1 (en) * | 2017-12-20 | 2024-10-02 | PI Industries Ltd. | Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same |
| US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| UA72611C2 (uk) | 2000-05-17 | 2005-03-15 | Орто-Макнейл Фармацевтикал, Інк. | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| NZ528270A (en) | 2001-03-19 | 2005-10-28 | Ono Pharmaceutical Co | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
| NZ585226A (en) * | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| JP5269087B2 (ja) * | 2007-11-16 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製のインヒビター |
-
2012
- 2012-09-18 ES ES12833476.0T patent/ES2632443T3/es active Active
- 2012-09-18 US US14/344,915 patent/US9012642B2/en not_active Expired - Fee Related
- 2012-09-18 EP EP12833476.0A patent/EP2757887B1/en active Active
- 2012-09-18 WO PCT/US2012/055838 patent/WO2013043553A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2757887A1 (en) | 2014-07-30 |
| EP2757887B1 (en) | 2017-04-26 |
| WO2013043553A1 (en) | 2013-03-28 |
| US9012642B2 (en) | 2015-04-21 |
| EP2757887A4 (en) | 2015-05-27 |
| US20140343092A1 (en) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2632443T3 (es) | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH | |
| JP7330312B2 (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| ES2688925T3 (es) | Tratamiento antiviral | |
| ES2645192T3 (es) | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH | |
| ES2707997T3 (es) | Compuestos de benzotiazol y su uso farmacéutico | |
| ES2624984T3 (es) | Derivados de ácido 2-(pirrolo[2,3-b]piridin-5-il)-2-(t-butoxi)-acético como inhibidores de la replicación del VIH para el tratamiento del SIDA | |
| ES2533863T3 (es) | Inhibidores novedosos de la transcriptasa inversa de VIH | |
| CN107108643B (zh) | 多环碳酰基吡啶酮化合物及其药物用途 | |
| JP5372751B2 (ja) | Ａｚａ−ペプチドプロテアーゼ阻害剤 | |
| KR20180129943A (ko) | 캡시드 조립 억제제를 포함하는 배합물 및 방법 | |
| US20090075939A1 (en) | Novel HIV reverse transcriptase inhibitors | |
| CA3106839A1 (en) | Inhibitors of hepatitis b virus | |
| JP2009525265A5 (es) | ||
| MX2010010082A (es) | Utilización de 4'-thio-2'-deoxinucleótidos como agentes anti-orthopoxvirus. | |
| WO2017051355A1 (en) | Compounds with hiv maturation inhibitory activity | |
| CN111511349A (zh) | 包含伊立替康或其药剂学上可接受的盐的用于口服给药的药剂学组合物 | |
| RU2018105352A (ru) | Производные бетулина для предупреждения или лечения ВИЧ-инфекций | |
| RU2018105343A (ru) | Производные бетулина для предупреждения или лечения ВИЧ-инфекций | |
| JP2022550387A (ja) | Ｔｌｒ７作用薬を含む薬物の組み合わせ | |
| Reviriego | Cenicriviroc mesylate | |
| HK1239676A1 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |